The record
| Class | growth hormone secretagogue |
|---|---|
| Also known as | CJC-1295, CJC-1295 no DAC, CJC-1295 without DAC, Modified GRF (1-29) |
| Chain length | - |
| Molecular weight | 3,367.9 Da |
| Half-life | 25-35 minutes |
| Route | SC |
| Studied for | Growth hormone deficiency (investigational); Anti-aging protocols; Body composition optimization; Metabolic syndrome (investigational) |
| Research use | GH secretion studies; Pituitary function assessment; Muscle protein synthesis research |
| What has been shown | Increases GH secretion 2-10 fold; Elevates IGF-1 levels 1.5-3 fold; Improves muscle repair and growth; Accelerates wound healing |
| How it works | Synthetic analog of growth hormone-releasing hormone (GHRH) with four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that enhance stability against enzymatic degradation. Binds to GHRH receptors on pituitary somatotrophs, activating adenylate cyclase and stimulating pulsatile release of endogenous growth hormone. Preserves natural GH pulsatility while enhancing trough GH levels. Unlike exog |
| Patent status | off patent |
| Regulatory status | research only |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Muscle Hypertrophy / Anabolic Signaling (affection, 72%)
- GH Pulsatility Environment (affection, 85%)
- Adult GH deficiency (illness, 60%)
- Anti-aging protocols (illness, 100%)
- Anti-aging therapy (illness, 60%)
- Body composition optimization (illness, 100%)
- Cognitive support (illness, 30%)
- Fat loss without muscle loss (illness, 30%)
- Growth hormone deficiency (illness, 100%)
- HIV-associated lipodystrophy (illness, 30%)
- Metabolic syndrome (illness, 100%)
- Pediatric growth hormone deficiency (illness, 60%)
- Visceral adiposity reduction (illness, 30%)
- Muscle loss or weakness (symptom, 67%)